INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
GT

Giordano Christopher Thomas

Director, CEOCIK 0001871714

EDGAR filingsOpen in network
Disclosed transactions6
Buys / sells5 / 0
Max Insider Score46
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
42
GT
Giordano Christopher ThomasDirector, CEO
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$11K
6,000 sh
Sep 11, 2026Sep 15, 2026
traded Sep 11, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    TENAX THERAPEUTICS, INC.Director, CEO · Nov 20, 2025
38
GT
Giordano Christopher ThomasDirector, CEO
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY
$8,837
4,850 sh
Sep 15, 2026
Sep 15, 2026
traded Sep 15, 2026
+0d
SEC FORM 4

Evidence

5
GT
Giordano Christopher ThomasDirector, CEO
TENXTENAX THERAPEUTICS, INC.
Grant or award
A—
450.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

38
GT
Giordano Christopher ThomasDirector, CEO
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$3,417
455 sh
Nov 19, 2025Nov 20, 2025
traded Nov 19, 2025
+1dSEC FORM 4

Evidence

46
GT
Giordano Christopher ThomasDirector, CEO
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$13K
1,612 sh
Nov 18, 2025Nov 20, 2025
traded Nov 18, 2025
+2dSEC FORM 4

Evidence

38
GT
Giordano Christopher ThomasDirector, CEO
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$4,083
538 sh
Nov 20, 2025Nov 20, 2025
traded Nov 20, 2025
+0dSEC FORM 4

Evidence